Compare Kimco Realty Corporation (HC) Common Stock (KIM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimco Realty Corporation (HC) Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.59 (market cap $15.02B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Kimco Realty Corporation (HC) Common Stock is far larger — about 3× Travere Therapeutics Inc. Common Stock's market cap, and Kimco Realty Corporation (HC) Common Stock pays a 5% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KIM | TVTX | |
|---|---|---|
Market Cap | $15.02B | $5.02B |
Volume | 4,636,202 | 2,060,842 |
Sector | Real Estate | Health |
52-Week High | $26.38 | $67.52 |
52-Week Low | $19.78 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $23.18B | $5.15B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KIM trades at $22.45, up 0.58% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Fundamentals show robust profitability with a 27.76% net income margin and a P/E of 26.1. Analyst consensus is a Buy with a $26.09 price target, though technical indicators suggest near-term caution.
The outlook for KIM is mixed; strong fundamentals and positive analyst sentiment support upside, but technical bearishness and macroeconomic risks pose challenges. Investment opportunity lies in its high dividend yield and earnings growth, while risks include market volatility and real estate sector headwinds. The stock's performance will hinge on upcoming earnings and broader economic conditions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kimco Realty Corporation (HC) Common Stock
Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.
Read more on KIM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
